Literature DB >> 12893748

Comparison of autologous and allogeneic hematopoietic stem cell transplantation for follicular lymphoma.

Koen van Besien1, Fausto R Loberiza, Ruta Bajorunaite, James O Armitage, Asad Bashey, Linda J Burns, Cesar O Freytes, John Gibson, Mary M Horowitz, David J Inwards, David I Marks, Rodrigo Martino, Richard T Maziarz, Arturo Molina, Santiago Pavlovsky, Andrew L Pecora, Harry C Schouten, Thomas C Shea, Hillard M Lazarus, J Douglas Rizzo, Julie M Vose.   

Abstract

In this article, we report on 904 patients undergoing transplantation for follicular lymphoma. A total of 176 (19%) received allogeneic, 131 (14%) received purged autologous, and 597 (67%) received unpurged autologous transplants. Five-year treatment-related mortality (TRM) rates were 30%, 14%, and 8% and 5-year recurrence rates were 21%, 43%, and 58% after allotransplantation, purged autotransplantation, and unpurged autotransplantation, respectively. In multivariate analyses, allotransplantation had higher TRM and lower disease recurrence. Purged autotransplantation had a 26% lower recurrence risk than unpurged autotransplantation. Five-year probabilities of survival were 51%, 62%, and 55% after allogeneic, purged autotransplantation, and unpurged autotransplantation, respectively. Advanced age, prolonged interval from diagnosis to transplantation, high lactate dehydrogenase (LDH), refractory disease, bone marrow involvement, low performance scores, and transplantation between 1990 and 1993 were associated with adverse outcomes. Total body irradiation was associated with higher TRM but lower recurrence. There was no association between acute or chronic graft-versus-host disease and recurrence after allotransplantation. We conclude that both allogeneic and autologous transplantation can induce durable remissions. There may be a benefit to graft purging in autologous transplantation. The decreased recurrence after allotransplantation is offset by increased TRM. We did not detect a correlation between graft-versus-host disease (GVHD) and recurrence. Finally, outcomes of transplantation for follicular lymphoma show improvement over the past decade.

Entities:  

Mesh:

Year:  2003        PMID: 12893748     DOI: 10.1182/blood-2003-04-1205

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  73 in total

Review 1.  The role of rituximab in autologous and allogeneic hematopoietic stem cell transplantation for non-Hodgkin's lymphoma.

Authors:  Elizabeth Naparstek
Journal:  Curr Hematol Malig Rep       Date:  2006-12       Impact factor: 3.952

Review 2.  Stem cell transplantation for indolent lymphoma and chronic lymphocytic leukemia.

Authors:  John G Gribben; Chitra Hosing; David G Maloney
Journal:  Biol Blood Marrow Transplant       Date:  2011-01       Impact factor: 5.742

3.  Autologous versus reduced-intensity allogeneic hematopoietic cell transplantation for patients with chemosensitive follicular non-Hodgkin lymphoma beyond first complete response or first partial response.

Authors:  Marcie R Tomblyn; Marian Ewell; Christopher Bredeson; Brad S Kahl; Stacey A Goodman; Mary M Horowitz; Julie M Vose; Robert S Negrin; Ginna G Laport
Journal:  Biol Blood Marrow Transplant       Date:  2010-11-10       Impact factor: 5.742

Review 4.  Novel immunotherapy approaches to follicular lymphoma.

Authors:  Christopher R Flowers; John P Leonard; Loretta J Nastoupil
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2018-11-30

Review 5.  Investigational strategies in autologous stem cell transplantation for follicular lymphoma.

Authors:  Oliver Weigert; Martin Dreyling; Michael Unterhalt; Wolfgang Hiddemann; Christian Buske
Journal:  Curr Oncol Rep       Date:  2006-09       Impact factor: 5.075

6.  High-dose cyclophosphamide and rituximab without stem cell transplant: a feasibility study for low grade B-cell, transformed and mantle cell lymphomas.

Authors:  Douglas E Gladstone; Javier Bolaños-Meade; Carol Ann Huff; Marianna Zahurak; Ian Flinn; Ivan Borrello; Leo Luznik; Ephraim Fuchs; Yvette Kasamon; William Matsui; Jonathan Powell; Hyam Levitsky; Robert A Brodsky; Richard Ambinder; Richard J Jones; Lode J Swinnen
Journal:  Leuk Lymphoma       Date:  2011-07-14

7.  T cell depleted stem-cell transplantation for adults with hematologic malignancies: sustained engraftment of HLA-matched related donor grafts without the use of antithymocyte globulin.

Authors:  Ann A Jakubowski; Trudy N Small; James W Young; Nancy A Kernan; Hugo Castro-Malaspina; Katherine C Hsu; Miguel-Angel Perales; Nancy Collins; Christine Cisek; Michelle Chiu; Marcel R M van den Brink; Richard J O'Reilly; Esperanza B Papadopoulos
Journal:  Blood       Date:  2007-08-23       Impact factor: 22.113

8.  Clinical outcomes of allogeneic stem cell transplantation for relapsed or refractory follicular lymphoma: a retrospective analysis by the Fukuoka Blood and Marrow Transplantation Group.

Authors:  Yoshikiyo Ito; Toshihiro Miyamoto; Tomohiko Kamimura; Ken Takase; Hideho Henzan; Yasuo Sugio; Koji Kato; Yuju Ohno; Tetsuya Eto; Takanori Teshima; Koichi Akashi
Journal:  Int J Hematol       Date:  2013-09-17       Impact factor: 2.490

Review 9.  Novel Therapy Approaches to Follicular Lymphoma.

Authors:  Michael Northend; William Townsend
Journal:  Drugs       Date:  2021-03       Impact factor: 9.546

10.  A comparison of HLA-identical sibling allogeneic versus autologous transplantation for diffuse large B cell lymphoma: a report from the CIBMTR.

Authors:  Hillard M Lazarus; Mei-Jie Zhang; Jeanette Carreras; Brandon M Hayes-Lattin; Asli Selmin Ataergin; Jacob D Bitran; Brian J Bolwell; César O Freytes; Robert Peter Gale; Steven C Goldstein; Gregory A Hale; David J Inwards; Thomas R Klumpp; David I Marks; Richard T Maziarz; Philip L McCarthy; Santiago Pavlovsky; J Douglas Rizzo; Thomas C Shea; Harry C Schouten; Shimon Slavin; Jane N Winter; Koen van Besien; Julie M Vose; Parameswaran N Hari
Journal:  Biol Blood Marrow Transplant       Date:  2009-10-04       Impact factor: 5.742

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.